BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 32886334)

  • 1. Stereotactic body radiotherapy versus hepatic resection for hepatocellular carcinoma (≤ 5 cm): a propensity score analysis.
    Sun J; Wang Q; Hong ZX; Li WG; He WP; Zhang T; Zhang AM; Fan YZ; Sun YZ; Zheng L; Duan XZ
    Hepatol Int; 2020 Sep; 14(5):788-797. PubMed ID: 32886334
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-Term Survival Analysis of Stereotactic Ablative Radiotherapy Versus Liver Resection for Small Hepatocellular Carcinoma.
    Su TS; Liang P; Liang J; Lu HZ; Jiang HY; Cheng T; Huang Y; Tang Y; Deng X
    Int J Radiat Oncol Biol Phys; 2017 Jul; 98(3):639-646. PubMed ID: 28581406
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biologically effective dose (BED) of stereotactic body radiation therapy (SBRT) was an important factor of therapeutic efficacy in patients with hepatocellular carcinoma (≤5 cm).
    Sun J; Zhang T; Wang J; Li W; Zhang A; He W; Zhang D; Li D; Ding J; Duan X
    BMC Cancer; 2019 Aug; 19(1):846. PubMed ID: 31455251
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatic Resection Versus Stereotactic Body Radiation Therapy Plus Transhepatic Arterial Chemoembolization for Large Hepatocellular Carcinoma: A Propensity Score Analysis.
    Sun J; Li WG; Wang Q; He WP; Wang HB; Han P; Zhang T; Zhang AM; Fan YZ; Sun YZ; Duan XZ
    J Clin Transl Hepatol; 2021 Oct; 9(5):672-681. PubMed ID: 34722182
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical outcomes and prognostic factors of cyberknife stereotactic body radiation therapy for unresectable hepatocellular carcinoma.
    Que J; Kuo HT; Lin LC; Lin KL; Lin CH; Lin YW; Yang CC
    BMC Cancer; 2016 Jul; 16():451. PubMed ID: 27405814
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic outcome and related predictors of stereotactic body radiotherapy for small liver-confined HCC: a systematic review and meta-analysis of observational studies.
    Long Y; Liang Y; Li S; Guo J; Wang Y; Luo Y; Wu Y
    Radiat Oncol; 2021 Apr; 16(1):68. PubMed ID: 33832536
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stereotactic body radiation therapy vs. radiofrequency ablation in Asian patients with hepatocellular carcinoma.
    Kim N; Cheng J; Jung I; Liang J; Shih YL; Huang WY; Kimura T; Lee VHF; Zeng ZC; Zhenggan R; Kay CS; Heo SJ; Won JY; Seong J
    J Hepatol; 2020 Jul; 73(1):121-129. PubMed ID: 32165253
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatectomy versus stereotactic body radiotherapy for primary early hepatocellular carcinoma: A propensity-matched analysis in a single institution.
    Nakano R; Ohira M; Kobayashi T; Ide K; Tahara H; Kuroda S; Shimizu S; Kimura T; Nagata Y; Aikata H; Chayama K; Ohdan H
    Surgery; 2018 Aug; 164(2):219-226. PubMed ID: 29801728
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long term outcomes of stereotactic body radiation therapy for hepatocellular carcinoma without macrovascular invasion.
    Mathew AS; Atenafu EG; Owen D; Maurino C; Brade A; Brierley J; Dinniwell R; Kim J; Cho C; Ringash J; Wong R; Cuneo K; Feng M; Lawrence TS; Dawson LA
    Eur J Cancer; 2020 Jul; 134():41-51. PubMed ID: 32460180
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alpha-fetoprotein normalization as a prognostic surrogate in small hepatocellular carcinoma after stereotactic body radiotherapy: a propensity score matching analysis.
    Jung J; Yoon SM; Han S; Shim JH; Kim KM; Lim YS; Lee HC; Kim SY; Park JH; Kim JH
    BMC Cancer; 2015 Dec; 15():987. PubMed ID: 26681337
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and Toxicity of Stereotactic Body Radiotherapy for Early to Advanced Stage Hepatocellular Carcinoma - Initial Experience From an Australian Liver Cancer Service.
    Liu HY; Lee Y; McLean K; Leggett D; Hodgkinson P; Fawcett J; Mott R; Stuart K; Pryor D
    Clin Oncol (R Coll Radiol); 2020 Oct; 32(10):e194-e202. PubMed ID: 32345457
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Repeated CyberKnife stereotactic body radiation therapy in hepatocellular carcinoma.
    Sun J; Ouyang C; Chang X; Zhang A; Wang Q; Li W; Zhang D; Wang J; Li D; Duan X
    Radiat Oncol; 2020 Jan; 15(1):10. PubMed ID: 31918728
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stereotactic body radiotherapy in hepatocellular carcinoma: patient selection and predictors of outcome and toxicity.
    Loi M; Comito T; Franzese C; Dominici L; Lo Faro L; Clerici E; Franceschini D; Mancosu P; Reggiori G; Gallo P; Badalamenti M; Scorsetti M
    J Cancer Res Clin Oncol; 2021 Mar; 147(3):927-936. PubMed ID: 32945972
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stereotactic body radiation therapy in recurrent hepatocellular carcinoma.
    Huang WY; Jen YM; Lee MS; Chang LP; Chen CM; Ko KH; Lin KT; Lin JC; Chao HL; Lin CS; Su YF; Fan CY; Chang YW
    Int J Radiat Oncol Biol Phys; 2012 Oct; 84(2):355-61. PubMed ID: 22342300
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stereotactic body radiation therapy as an effective and safe treatment for small hepatocellular carcinoma.
    Zhang T; Sun J; He W; Li H; Piao J; Xu H; Duan X
    BMC Cancer; 2018 Apr; 18(1):451. PubMed ID: 29678159
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term survival analysis in combined transarterial embolization and stereotactic body radiation therapy versus stereotactic body radiation monotherapy for unresectable hepatocellular carcinoma >5 cm.
    Su TS; Lu HZ; Cheng T; Zhou Y; Huang Y; Gao YC; Tang MY; Jiang HY; Lian ZP; Hou EC; Liang P
    BMC Cancer; 2016 Nov; 16(1):834. PubMed ID: 27809890
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Baseline Albumin-Bilirubin (ALBI) Score in Western Patients With Hepatocellular Carcinoma Treated With Stereotactic Body Radiation Therapy (SBRT).
    Murray LJ; Sykes J; Brierley J; Kim JJ; Wong RKS; Ringash J; Craig T; Velec M; Lindsay P; Knox JJ; Dawson LA
    Int J Radiat Oncol Biol Phys; 2018 Jul; 101(4):900-909. PubMed ID: 29976502
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes After Stereotactic Body Radiotherapy or Radiofrequency Ablation for Hepatocellular Carcinoma.
    Wahl DR; Stenmark MH; Tao Y; Pollom EL; Caoili EM; Lawrence TS; Schipper MJ; Feng M
    J Clin Oncol; 2016 Feb; 34(5):452-9. PubMed ID: 26628466
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Better survival after stereotactic body radiation therapy following transarterial chemoembolization in nonresectable hepatocellular carcinoma: A propensity score matched analysis.
    Wong TC; Chiang CL; Lee AS; Lee VH; Yeung CS; Ho CH; Cheung TT; Ng KK; Chok SH; Chan AC; Dai WC; Wong FC; Luk MY; Leung TW; Lo CM
    Surg Oncol; 2019 Mar; 28():228-235. PubMed ID: 30851906
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stereotactic body radiotherapy versus intensity-modulated radiotherapy for hepatocellular carcinoma with portal vein tumor thrombosis.
    Li LQ; Zhou Y; Huang Y; Liang P; Liang SX; Su TS
    Hepatol Int; 2021 Jun; 15(3):630-641. PubMed ID: 33818714
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.